Rhd Alloimmunization in Pregnancy
Özet
RHD alloimmunization occurs when RhD-negative women develop antibodies after exposure to RhD-positive fetal blood, leading to hemolytic disease of the newborn. This condition can result in severe fetal anemia, making early diagnosis and management crucial. Anti-D immune globulin has significantly reduced RhD alloimmunization by preventing the maternal immune system from producing harmful antibodies.
The prevalence of RhD-negative blood varies globally. It is highest among the Basque population (30–35%) and around 15% among white North Americans and Europeans. Other populations have lower rates of RhD-negative individuals, influencing the global occurrence of alloimmunization.
Screening for RhD-negative status and antibody testing in the first trimester is essential. If antibodies are detected, fetal anemia is monitored using Doppler ultrasonography. In severe cases, intrauterine transfusions may be required. Management differs between first and subsequent pregnancies, with closer monitoring for women who have had previous RhD-positive pregnancies.
Preventive measures, including anti-D immune globulin administration, are key in reducing the risk. Advanced options, such as in vitro fertilization with RhD-negative embryos, are considered for high-risk cases. With modern treatments, RhD alloimmunization is now a manageable condition, improving outcomes for both mothers and infants.
RHD alloimmunizasyonu, RhD-negatif kadınların RhD-pozitif fetal kana maruz kalması sonucunda anti-D antikorları üretmesiyle meydana gelir ve bu durum, yenidoğan hemolitik hastalığına yol açabilir. Bu durum, ciddi fetal anemiye neden olabilir, bu nedenle erken teşhis ve uygun yönetim hayati önem taşır. Anti-D immünoglobulin uygulaması, maternal bağışıklık sisteminin zararlı antikorlar üretmesini engelleyerek, RHD alloimmunizasyonunun sıklığını ve buna bağlı komplikasyonları önemli ölçüde azaltmıştır.
RhD-negatif kan grubu, dünya genelinde farklı oranlarda görülmektedir. En yüksek prevalans, Bask populasyonunda (%30–35) görülür. Kuzey Amerikalılar ile Avrupalılarda yaklaşık %15 civarındadır. Diğer popülasyonlarda ise RhD-negatif birey oranı daha düşüktür. Bu varyasyonlar, alloimmunizasyonun küresel dağılımını etkileyen önemli faktörlerdir.
Gebeliğin ilk trimesterinde RhD-negatif kadınlarda kan grubu ve antikor taraması yapılmalıdır. Antikor varlığı tespit edilirse, fetal anemi Doppler ultrasonografi ile izlenir. Ciddi anemi durumunda intrauterin kan transfüzyonu gerekebilir. Yönetim, ilk gebelik ya da önceki RhD-pozitif gebeliklerin varlığına göre farklılık gösterir; önceden alloimmunizasyon olan kadınlar daha sık izlenmelidir.
Anti-D immünoglobulin uygulaması, alloimmunizasyon riskini azaltmada temel önlemdir. Yüksek riskli vakalarda, RhD-negatif embriyolarla in vitro fertilizasyon gibi ileri düzey tedavi seçenekleri de değerlendirilebilir. Modern tıbbi yaklaşımlar sayesinde, RHD alloimmunizasyonu artık yönetilebilir bir durum haline gelmiş ve anne-bebek sağlığı üzerindeki olumsuz etkileri azaltılmıştır.
Referanslar
Bhutani VK, Zipursky A, Blencowe H, Khanna R, Sgro M, Ebbesen F, et al. Neonatal hyperbilirubinemia and Rhesus disease of the newborn: incidence and impairment estimates for 2010 at regional and global levels. Pediatric research. 2013;74(1):86-100.
Zipursky A, Paul VK. The global burden of Rh disease. Archives of Disease in Childhood-Fetal and Neonatal Edition. 2011;96(2):F84-F5.
Bergström H, Nilsson L-Å, Nilsson L, Ryttinger L. Demonstration of Rh antigens in a 38-day-old fetus. American Journal of Obstetrics and Gynecology. 1967;99(1):130-3.
Medearis AL, Hensleigh PA, Parks DR, Herzenberg LA. Detection of fetal erythrocytes in maternal blood post partum with the fluorescence-activated cell sorter. American journal of obstetrics and gynecology. 1984;148(3):290-5.
Lappen JR, Stark S, Gibson KS, Prasad M, Bailit JL. Intravenous drug use is associated with alloimmunization in pregnancy. American Journal of Obstetrics and Gynecology. 2016;215(3):344. e1-. e6.
Kumpel BM. On the immunologic basis of Rh immune globulin (anti‐D) prophylaxis. Transfusion. 2006;46(9):1652-6.
Hadley AG. Laboratory assays for predicting the severity of haemolytic disease of the fetus and newborn. Transplant immunology. 2002;10(2-3):191-8.
Nicolaides K, Thilaganathan B, Rodeck C, Mibashan R. Erythroblastosis and reticulocytosis in anemic fetuses. American journal of obstetrics and gynecology. 1988;159(5):1063-5.
Sperling JD, Dahlke JD, Sutton D, Gonzalez JM, Chauhan SP. Prevention of RhD alloimmunization: a comparison of four national guidelines. American journal of perinatology. 2018;35(02):110-9.
Finck R, Lui‐Deguzman C, Teng SM, Davis R, Yuan S. Comparison of a gel microcolumn assay with the conventional tube test for red blood cell alloantibody titration. Transfusion. 2013;53(4):811-5.
Nicolaides K, Rodeck C. Maternal serum anti-D antibody concentration and assessment of rhesus isoimmunisation. BMJ: British Medical Journal. 1992;304(6835):1155.
Picklesimer AH, Oepkes D, Moise Jr KJ, Kush ML, Weiner CP, Harman CR, et al. Determinants of the middle cerebral artery peak systolic velocity in the human fetus. American journal of obstetrics and gynecology. 2007;197(5):526. e1-. e4.
Mari G, Deter RL, Carpenter RL, Rahman F, Zimmerman R, Moise Jr KJ, et al. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. New England Journal of Medicine. 2000;342(1):9-14.
Mari G, Norton ME, Stone J, Berghella V, Sciscione AC, Tate D, et al. Society for Maternal-Fetal Medicine (SMFM) Clinical Guideline# 8: the fetus at risk for anemia–diagnosis and management. American journal of obstetrics and gynecology. 2015;212(6):697-710.
Moise Jr KJ, Argoti PS. Management and prevention of red cell alloimmunization in pregnancy: a systematic review. Obstetrics & Gynecology. 2012;120(5):1132-9.
Klumper FJ, van Kamp IL, Vandenbussche FP, Meerman RH, Oepkes D, Scherjon SA, et al. Benefits and risks of fetal red-cell transfusion after 32 weeks gestation. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2000;92(1):91-6.
